N-ureidoalkyl-piperidines as modulators of chemokine receptor activity

A compound of formula (I):

• or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
• R1 is selected from C1-6 alkyl, a (CH2)r—C3-10 carbocyclic residue substituted with 0-5 R5 and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R5;
• R2, at each occurrence, is selected from NR4fC(O)(CHR′)rR4b, NR4fC(O)H, NR4fS(O)2(CHR′)rR4b, and NR4fC(O)OR4b;
• R4b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C1-3 perflouroalkyl, a (CH2)r—C3-6 carbocyclic residue substituted with 0-3 R4e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R4e;
• R4e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR4fR4f, and (CH2)rphenyl;
• R4f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
• alternatively, R4b and R4f join to form a 5, 6, or 7-membered ring containing from 0-1 additional heteroatoms selected from N and O, the ring being subsituted with 0-1 Rf;
• Rf, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
• R5, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, NO2, CN, (CHR′)rNR5aR5a, (CHR′)rOH, (CHR′)rO(CHR′)rR5d, (CHR′)rSH, (CHR′)rC(O)H, (CHR′)rS(CHR′)rR5d, (CHR′)rC(O)OH, (CHR′)rC(O)(CHR′)rR5b, (CHR′)rC(O)NR5aR5a, (CHR′)rNR5fC(O)(CHR′)rR5b, (CHR′)rC(O)O(CHR′)rR5d, (CHR′)rOC(O)(CHR′)rR5b, (CHR′)rC(═NR5f)NR5aR5a, (CHR′)rNHC(═NR5f)NR5fR5f, (CHR′)rS(O)p(CHR′)rR5b, (CHR′)rS(O)2NR5aR5a, (CHR′)rNR5fS(O)2(CHR′)rR5b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R′, C2-8 alkynyl substituted with 0-3 R′, (CHR′)rphenyl substituted with 0-3 R5e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R5e;
• R5a, at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r—C3-10 carbocyclic residue substituted with 0-5 R5e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R5e;
• R5b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r—C3-6 carbocyclic residue substituted with 0-3 R5e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R5e;
• R5d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R5e, a (CH2)r—C3-10 carbocyclic residue substituted with 0-3 R5e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R5e;
• R5e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR5fR5f, and (CH2)rphenyl;
• R5f, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
• R′, at each occurrence, is selected from H and C1-6 alkyl,;
• r is selected from 0, 1, 2, 3, 4, and 5;
• and
• p is selected from 0, 1, and 2.